Kidney and heart disease risk climbs fast after a type 2 diabetes diagnosis, study finds

More than half of people newly diagnosed with type 2 diabetes will go on to develop chronic kidney disease, heart failure or die within a decade, according to a large real-world analysis of more than 1.6 million patients presented Monday at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan. The study is among the largest of its kind to track, in fine detail, how quickly cardiovascular and kidney damage accumulates after a diabetes diagnosis, and how often the two conditions feed into each other.

The analysis, led by Naveed Sattar, a professor of metabolic medicine at the University of Glasgow's School of Cardiovascular and Metabolic Health, drew on anonymized American health records to reconstruct, patient by patient, the years-long path from a type 2 diabetes diagnosis to serious organ damage. Researchers say the findings argue for treating diabetes as a whole-body threat from the moment of diagnosis, rather than managing blood sugar in isolation and waiting for complications to appear.

What the numbers show

Researchers followed 1,617,508 adults newly diagnosed with type 2 diabetes in the United States between January 2010 and March 2024, drawing on data from the CALOR real-world evidence programme. The average participant was 59 years old at diagnosis, and 51 percent were female. Among the smaller subset with body mass index recorded, the average was 30.9, in the obese range; 72 percent of participants already had abnormal blood fats and 68 percent had high blood pressure at the time of their diabetes diagnosis.

The core finding is a steep climb in combined risk over time. Within five years of a type 2 diabetes diagnosis, 33 percent of patients had developed chronic kidney disease or heart failure, or had died. Within ten years, that combined risk rose to 55 percent.

• Within five years, 19.0 percent of patients developed chronic kidney disease first, versus 8.3 percent who developed heart failure first.
• Among those who developed heart failure first, 42 percent went on to develop chronic kidney disease within the following five years.
• Among those who developed chronic kidney disease first, 23 percent went on to develop heart failure within the following five years.
• The overall combined risk of kidney disease, heart failure or death reached 33 percent at five years and 55 percent at ten years.

That cross-over pattern, in which one organ's failure accelerates damage to the other, is what researchers describe as a vicious cycle: kidneys and heart share blood vessels, and damage to one organ raises blood pressure and fluid retention that stresses the other.

How the picture has changed

Type 2 diabetes has long been understood as a disease that raises the odds of heart attack, stroke, kidney failure and blindness, but the exact tempo of that damage, and how one complication tends to trigger the next, has been harder to pin down in everyday clinical populations rather than tightly controlled trials. The new analysis draws on the CALOR programme, an observational research effort sponsored by AstraZeneca that mines de-identified health records across the United States, the United Kingdom and Japan to map how obesity, diabetes and cardiovascular-kidney-metabolic disease intersect in practice, outside the more selective populations enrolled in drug trials.

Diabetes remains extremely common. More than 40 million people in the United States have diagnosed or undiagnosed diabetes, according to the Centers for Disease Control and Prevention's most recent national statistics report, and type 2 disease accounts for the large majority of those cases. Clinical guidelines from groups including the American Diabetes Association and EASD have shifted in recent years toward treating cardiovascular and kidney risk alongside blood sugar from the outset, favoring drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists partly because trials showed they protect the heart and kidneys as well as lowering glucose. The new Glasgow-led data adds a real-world timeline to that guidance, showing just how fast the clock is already running by the time many patients are diagnosed.

Who is affected

The population studied mirrors the broader type 2 diabetes population in wealthy countries: people diagnosed in late middle age, disproportionately carrying excess weight, and often already living with high blood pressure or abnormal cholesterol before diabetes is even detected. Because the analysis relied on U.S. health system records, the authors caution that people without regular access to care, including many uninsured or under-insured patients, may be underrepresented, and that body mass index was recorded for only a small share of the cohort, limiting how precisely obesity's role could be measured. The researchers also flagged gaps in racial and ethnic data that limit conclusions about disparities in outcomes.

What researchers are saying

Sattar, who has published widely on cardiometabolic disease, framed the results as a call to treat diabetes comprehensively rather than sequentially.

"Our findings clearly show how serious complications associated with type 2 diabetes rise sharply over time as obesity, abnormal blood fats, high blood pressure and higher blood sugar damages blood vessels and vital organs."

The team also noted the limits of an observational study: it can show strong associations between diabetes and organ damage over time, but cannot by itself prove that any single factor causes another, since patients were not randomly assigned to different treatment approaches. Independent outlets covering the presentation, including Medical Xpress and News-Medical, both noted that the research underscores calls for earlier, more holistic management of newly diagnosed patients rather than a narrow focus on glucose control.

What happens next

The findings were presented as a conference abstract in Milan and are expected to appear in a supplement volume of the journal Diabetologia following the meeting, which runs through October 2. Researchers say the next step is to test whether earlier, combined treatment of blood sugar, blood pressure, cholesterol and weight, rather than sequential management of each risk factor after it worsens, can blunt the climb in complication rates the study documents.

For now, the authors say the practical message for doctors and patients is straightforward: the five-year and ten-year risk figures give a concrete timeline for screening decisions, such as how often to check kidney function or watch for early signs of heart strain, in the years immediately following a type 2 diabetes diagnosis, rather than waiting for symptoms to appear.